Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Freegold Intersects 3.62 g/t Au over 42m and 1.23 g/t Au over 170.7m (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Antiaging Quantum Living Inc AAQL

Antiaging Quantum Living Inc. is an investment holding company. It focuses on Website development, maintenance and online business advertisement. Its primary business operations are conducted through its subsidiaries AAQL Inc., AAQL HK Limited, Antiaging Doctor Hangzhou Holding LTD (Dao Ling Doctor Hangzhou), Dao Ling Doctor (Zhejiang) Health Management Limited (Dao Ling Doctor Zhejiang), and... see more

Recent & Breaking News (OTCPK:AAQL)

Merck (MRK) to pay triple last closing price for Idenix Pharmaceuticals (IDIX)

Canadian Press June 9, 2014

Catching Hepatitis: Why Merck (MRK) Was Willing to Break the Bank for Idenix (IDIX)

Equities.com June 9, 2014

Achillion Reports First Quarter 2014 Financial Results

GlobeNewswire May 7, 2014

Achillion to Present at Three Upcoming Investor Conferences

GlobeNewswire May 1, 2014

Achillion Advances ACH-3422, Uridine-Analog Nucleotide Inhibitor, Into Clinical Trial; Initiates Phase 2 Pilot Study With ACH-3102, NS5A Inhibitor, for HCV

GlobeNewswire April 30, 2014

Achillion Announces Oral Presentations Given at APASL 2014 Detailing Clinical Activity of ACH-3102, Second-Generation NS5A Inhibitor, Against Genotype 1b HCV

GlobeNewswire March 14, 2014

Achillion Reports 2013 Fourth Quarter and Year-End Financial Results

GlobeNewswire March 7, 2014

Achillion to Present at Two Upcoming Investor Conferences

GlobeNewswire February 10, 2014

Achillion Reports HCV Pipeline Progress and Outlines 2014 HCV Milestones

Globe Newswire January 13, 2014

ACHILLION PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Achillion Pharmaceuticals, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of December 9, 2013 -- ACHN

PR Newswire December 6, 2013

ACHILLION PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Achillion Pharmaceuticals, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of December 9, 2013 -- ACHN

Marketwired December 2, 2013

ACHN, CTIC, DRYS and FREE added to NASDAQ Active Stock Watch List at GSR

Accesswire December 2, 2013

Achillion to Present at the Three Upcoming Healthcare Conferences

Globe Newswire November 26, 2013

ACHILLION PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Achillion Pharmaceuticals, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of December 9, 2013

Business Wire November 22, 2013

SAREHOLDER ALERT: Pomerantz Law Firm has filed a Class Action Against Achillion Pharmaceutical, Inc. and Certain Officers - ACLN

PR Newswire November 22, 2013

Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of $100,000 Investing in Achillion Pharmaceuticals, Inc. to Contact the Firm

Marketwired November 15, 2013

ACHILLION PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Achillion Pharmaceuticals, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of December 9, 2013 -- ACHN

Globe Newswire November 13, 2013

Achillion Reiterates HCV Pipeline Priorities and Reports Third Quarter and Nine Month 2013 Financial Results

Globe Newswire November 12, 2013

Achillion to Present at the Credit Suisse Healthcare Conference

Globe Newswire November 11, 2013

SHAREHOLDER ALERT: Pomerantz Law Firm Has Filed a Class Action Against Achillion Pharmaceutical, Inc. and Certain Officers -- ACHN

Marketwired November 8, 2013